

Evolve Global Healthcare Enhanced Yield Fund

June 30, 2023

Interim Management Report of Fund Performance

This interim management report of fund performance contains financial highlights but does not contain the complete interim financial statements of the investment fund. You can get a copy of the interim financial statements at your request, and at no cost, by calling 1-844-370-4884, by writing to us at Evolve Funds, 40 King Street West, Suite 3404, Toronto, ON, M5H 3Y2 or by visiting our website at www.evolveetfs.com or SEDAR at www.sedar.com. You may also contact us using one of these methods to request a copy of the investment fund's proxy voting policies and procedures, proxy voting disclosure record, or quarterly portfolio disclosure.

Evolve Global Healthcare Enhanced Yield Fund

June 30, 2023

Investment Objective and Strategies

The Evolve Global Healthcare Enhanced Yield Fund (the "Fund") seeks to replicate, to the extent reasonably possible before fees and expenses, the performance of the Solactive Global Healthcare 20 Index (the "Benchmark"), or any successor thereto, while mitigating downside risk. The Fund seeks to capture global opportunities in the healthcare sector, fueled by steady population growth, an aging demographic, and increased demand for healthcare stemming from growing prosperity and innovative developments in the sector. The Fund invests primarily in the equity constituents of the Solactive Global Healthcare 20 Index, or any successor thereto, while writing covered call options on up to 33% of the portfolio securities, at the discretion of the portfolio manager. The level of covered call option writing may vary based on market volatility and other factors.

Risk

There were no changes to the Fund over the period of this report that materially affected the level of risk associated with an investment in the Fund. Prospective investors should read the Fund's most recent prospectus and consider the description of risks contained therein.

Results of Operations

For the six-month period ended June 30, 2023, the Unhedged ETF Units returned 0.4% versus the Solactive Global Healthcare 20 Index return of 1.1%. The Hedged ETF Units returned 1.8% versus the Solactive Global Healthcare 20 Canadian Dollar Index Hedged return of 1.0%. The US Dollar Unhedged ETF Units returned 2.7% versus the Solactive Global Healthcare 20 Index return of 1.1%. The Hedged Class A Mutual Fund Units returned 1.3% and the Hedged Class F Mutual Fund Units returned 1.9% versus the Solactive Global Healthcare 20 Canadian Dollar Index Hedged return of 1.0%. The difference in performance of the hedged units relative to its benchmark can be attributed primarily to management and administration fees plus applicable sales taxes and to portfolio trading and hedging strategies. The difference in performance of the unhedged units relative to its benchmark can be attributed primarily to management and administration fees plus applicable sales taxes and to portfolio trading. Furthermore, the difference can also be attributed to the implementation of the call writing strategy where the Fund tend to outperform in flat or down markets and underperform during sharp market advances. This performance difference can be seen over the period the calls are written, typically with one to two months to expiry, and then resets when new option positions are established. The Fund's net assets were \$271.7MM as at June 30, 2023.

Portfolio Manager Commentary

The healthcare sector saw exciting developments in the first half of 2023, with key advancements in treatments and macroeconomic factors impacting both pharmaceutical and biotech companies. As COVID-19 fades from the headlines, healthcare companies who once relied heavily on sales of COVID-19 vaccines and treatments, such as Pfizer, Moderna and Eli Lilly, saw a steep decline in revenues from their COVID-19 related products. As a result, several companies within the sector faced the challenge of transitioning away from pandemic-driven demand for COVID-19 treatments towards more stable products for a post-pandemic market. This shift put pressure on Pfizer and other similar companies to diversify their product portfolios and adapt to the new healthcare landscape.¹

In April, AstraZeneca delivered positive Q1 2023 results reporting rising profits, fueled largely by the performance of its oncology treatments. With a robust pipeline and plans to initiate 30 advanced stage trials this year, AstraZeneca is demonstrating a proactive approach towards fortifying its position as a leading producer of cancer therapies. These trials could offer a significant opportunity for growth, underlining the potential of innovative treatments in oncology.²

Meanwhile, the race to develop obesity drugs emerged as a key theme in the healthcare industry, with companies like Eli Lilly & Co. and Novo Nordisk A/S leading the charge. Both companies have seen incredible success resulting from their obesity treatments. In fact, when Novo Nordisk announced Q1 2023 earnings, the company reported 68% revenue growth for their key weight-loss drug Ozempic. The injectable drug was the company's top-selling product, accounting for 37% of total revenue.³ Their experimental obesity pills have also shown promising results, setting the stage for potential growth in a market estimated to be worth up to \$100 billion. However, some companies have not seen such success in the weight-loss market, with Pfizer halting trials of a weight loss pill it had in development due to safety concerns underscores the challenges and risks inherent in drug development.⁴

Performance Attribution

For the six month period ending June 30, 2023, Eli Lilly And Co made the biggest contribution to the Fund, followed by Stryker Corporation. By weight, the Fund's largest holdings were Intuitive Surgical Inc, Eli Lilly And Co, and Medtronic PLC.

(1) <https://www.fiercepharma.com/pharma/pfizer-sees-covid-19-vaccine-sales-falling-64-2023-paxlovid-declining-58>

Evolve Global Healthcare Enhanced Yield Fund

June 30, 2023

(2) <https://www.bloomberg.com/news/articles/2023-04-27/astra-profit-beats-estimates-before-key-cancer-trial-results>

(3) <https://www.fool.com/investing/2023/07/06/ozempic-sales-are-soaring-heres-why-they-could-go/>

(4) <https://www.bnnbloomberg.ca/the-race-to-develop-weight-loss-pills-has-some-drugmakers-falling-behind-1.1938223>

Related Party Transactions

Evolve Funds Group Inc. (the "Manager") complies with its current policy and procedures regarding investments in related issuers and reports periodically to the Independent Review Committee.

Management Fees

The Manager is entitled to an annual management fee of 0.45% of the net asset value of the Hedged, Unhedged and US Dollar Unhedged ETF Units and the Hedged Class F Mutual Fund Units and 1.45% of the net asset value of the Hedged Class A Mutual Fund Units of the Fund, accrued daily and generally paid monthly in arrears. For the six-month period ended June 30, 2023, the Fund incurred \$676,369 in management fees. These management fees were received by the Manager for the day-to-day operations of the fund, including managing the portfolio, maintaining portfolio systems used to manage the Fund, maintaining the www.evolveefs.com website, and providing all other services including marketing and promotion.

Administration Fees

The administration fees are calculated based on 0.15% per annum of the average daily net asset value of the Fund. The fees are accrued daily and are generally paid monthly. For the six-month period ended June 30, 2023, the Fund incurred \$224,973 in administration fees. These administration fees were received by the Manager for the following operating expenses of the Fund including but not limited to: mailing and printing expenses for periodic reports to unitholders; fees payable to the index provider, Registrar and Transfer Agent and Custodian; any reasonable out of pocket expenses incurred by the Manager or its agents in connection with their ongoing obligations to the Fund; IRC committee member fees and expenses in connection with the IRC; expenses related to compliance with NI 81-107; fees and expenses relating to voting of proxies by a third party; insurance coverage for the members of the IRC; fees payable to the auditors and legal advisors of the Fund; regulatory filing, stock exchange and licensing fees and CDS fees; costs and expenses of complying with all applicable laws, regulations and policies, including expenses and costs incurred in connection with the continuous public filing requirements such as permitted prospectus preparation and filing expenses; and legal, accounting and audit fees and fees and expenses of the Trustee, Custodian and Manager which are incurred in respect of matters not in the normal course of the Fund's activities. The administration fee paid to the Manager by the Fund may, in any particular period, be less than or exceed the operating expenses that the Manager incurs for the Fund.

Evolve Global Healthcare Enhanced Yield Fund

June 30, 2023

Financial Highlights

The following tables show selected key financial information about the Fund and are intended to help readers understand the Fund's financial performance for the period indicated.

The Fund's Net Assets Per Unit¹

	June 30, 2023	December 31, 2022	December 31, 2021	December 31, 2020	December 31, 2019	December 31, 2018
For the periods ended:	(\$)	(\$)	(\$)	(\$)	(\$)	(\$)
Unhedged ETF Units - Net Assets per Unit						
Net Assets per Unit, beginning of period	24.87	25.48	23.16	22.71	21.10	19.02
Increase (decrease) from operations:						
Total revenue	0.39	0.75	0.54	0.65	0.68	0.60
Total expenses	(0.17)	(0.26)	(0.24)	(0.27)	(0.28)	(0.54)
Realized gains (losses)	1.27	(0.46)	0.66	0.35	0.24	(3.16)
Unrealized gains (losses)	(1.40)	1.18	2.90	0.42	2.40	3.51
Total increase (decrease) from operations²	0.09	1.21	3.86	1.15	3.04	0.41
Distributions:						
From income (excluding dividends)	(0.96)	-	-	-	-	-
From dividends	-	(0.47)	(0.28)	(0.25)	(0.27)	-
From capital gains	-	-	(0.87)	(0.75)	-	-
Return of capital	-	(1.33)	(0.38)	(0.50)	(1.07)	(0.87)
Total annual distributions³	(0.96)	(1.80)	(1.53)	(1.50)	(1.34)	(0.87)
Net Assets per Unit, end of period	24.02	24.87	25.48	23.16	22.71	21.10
Hedged ETF Units - Net Assets per Unit						
Net Assets per Unit, beginning of period	21.88	23.59	21.14	21.14	18.79	19.28
Increase (decrease) from operations:						
Total revenue	0.35	0.69	0.46	0.55	0.59	0.51
Total expenses	(0.15)	(0.24)	(0.23)	(0.23)	(0.26)	(0.45)
Realized gains (losses)	1.52	(1.18)	0.19	1.17	0.17	0.68
Unrealized gains (losses)	(1.34)	1.10	3.70	0.53	3.96	(1.20)
Total increase (decrease) from operations²	0.38	0.37	4.12	2.02	4.46	(0.46)
Distributions:						
From income (excluding dividends)	(0.96)	-	-	-	-	-
From dividends	-	(0.42)	(0.23)	(0.34)	(0.27)	-
From capital gains	-	-	(0.88)	(0.69)	-	-
Return of capital	-	(1.38)	(0.42)	(0.47)	(1.07)	(0.87)
Total annual distributions³	(0.96)	(1.80)	(1.53)	(1.50)	(1.34)	(0.87)
Net Assets per Unit, end of period	21.30	21.88	23.59	21.14	21.14	18.79

Evolve Global Healthcare Enhanced Yield Fund

June 30, 2023

The Fund's Net Assets Per Unit¹ (cont'd)

For the periods ended:	June 30, 2023 (\$)	December 31, 2022 (\$)	December 31, 2021 (\$)	December 31, 2020 (\$)	December 31, 2019 (\$)	December 31, 2018 (\$)
US Dollar Unhedged ETF Units - Net Assets per Unit⁵						
Net Assets per Unit, beginning of period	28.82	29.80	27.21	26.91	26.64	N/A
Increase (decrease) from operations:						
Total revenue	0.46	0.85	0.59	0.78	0.03	N/A
Total expenses	(0.19)	(0.30)	(0.28)	(0.33)	(0.02)	N/A
Realized gains (losses)	1.47	(0.42)	0.76	0.38	(0.07)	N/A
Unrealized gains (losses)	(1.59)	2.06	3.56	0.70	0.52	N/A
Total increase (decrease) from operations²	0.15	2.19	4.63	1.53	0.46	N/A
Distributions:						
From income (excluding dividends)	(1.29)	-	-	-	-	N/A
From dividends	-	(0.56)	(0.31)	(0.33)	(0.15)	N/A
From capital gains	-	-	(1.09)	(0.99)	-	N/A
Return of capital	-	(1.99)	(0.52)	(0.69)	-	N/A
Total annual distributions³	(1.29)	(2.55)	(1.92)	(2.01)	(0.15)	N/A
Net Assets per Unit, end of period	27.64	28.82	29.80	27.21	26.91	N/A
Hedged Class A - Net Assets per Unit⁴						
Net Assets per Unit, beginning of period	19.48	21.48	19.59	19.90	N/A	N/A
Increase (decrease) from operations:						
Total revenue	0.31	0.61	0.45	0.26	N/A	N/A
Total expenses	(0.24)	(0.44)	(0.44)	(0.20)	N/A	N/A
Realized gains (losses)	1.34	(1.06)	0.36	0.62	N/A	N/A
Unrealized gains (losses)	(1.21)	(0.13)	2.97	0.08	N/A	N/A
Total increase (decrease) from operations²	0.20	(1.02)	3.34	0.76	N/A	N/A
Distributions:						
From income (excluding dividends)	(0.96)	-	-	-	N/A	N/A
From dividends	-	(0.20)	(0.03)	(0.31)	N/A	N/A
From capital gains	-	-	(1.06)	(0.21)	N/A	N/A
Return of capital	-	(1.60)	(0.44)	(0.10)	N/A	N/A
Total annual distributions³	(0.96)	(1.80)	(1.53)	(0.62)	N/A	N/A
Net Assets per Unit, end of period	18.75	19.48	21.48	19.59	N/A	N/A

Evolve Global Healthcare Enhanced Yield Fund

June 30, 2023

The Fund's Net Assets Per Unit¹ (cont'd)

For the periods ended:	June 30, 2023 (\$)	December 31, 2022 (\$)	December 31, 2021 (\$)	December 31, 2020 (\$)	December 31, 2019 (\$)	December 31, 2018 (\$)
Hedged Class F - Net Assets per Unit⁴						
Net Assets per Unit, beginning of period	20.32	22.05	19.85	19.89	N/A	N/A
Increase (decrease) from operations:						
Total revenue	0.30	0.63	0.41	0.26	N/A	N/A
Total expenses	(0.13)	(0.22)	(0.21)	(0.10)	N/A	N/A
Realized gains (losses)	1.52	(1.21)	0.02	0.35	N/A	N/A
Unrealized gains (losses)	(1.00)	1.28	3.86	0.29	N/A	N/A
Total increase (decrease) from operations²	0.69	0.48	4.08	0.80	N/A	N/A
Distributions:						
From income (excluding dividends)	(0.96)	-	-	-	N/A	N/A
From dividends	-	(0.39)	(0.21)	(0.22)	N/A	N/A
From capital gains	-	-	(0.87)	(0.25)	N/A	N/A
Return of capital	-	(1.41)	(0.45)	(0.16)	N/A	N/A
Total annual distributions³	(0.96)	(1.80)	(1.53)	(0.63)	N/A	N/A
Net Assets per Unit, end of period	19.72	20.32	22.05	19.85	N/A	N/A

- 1 This information is derived from the Fund's unaudited interim financial statements as at June 30, 2023 and the audited annual financial statements as at December 31, 2022, 2021, 2020, 2019, and 2018. The Unhedged and Hedged ETF Units effectively began operations on October 23, 2017, the US Dollar Unhedged ETF Units effectively began operations on November 26, 2019 and the Hedged Class A and F Mutual Fund Units effectively began operations on July 7, 2020.
- 2 Net assets and distributions are based on the actual number of units outstanding at the relevant time. The increase (decrease) from operations is based on the weighted average number of units outstanding over the period.
- 3 Distributions were paid in cash or reinvested in additional units of the Fund, or both. Actual distributions may vary slightly owing to rounding.
- 4 This amount represents the initial launch price.
- 5 Per unit figures are stated in CAD equivalent.

The Fund's Ratios/Supplemental Data

For the periods ended:	June 30, 2023	December 31, 2022	December 31, 2021	December 31, 2020	December 31, 2019	December 31, 2018
Unhedged ETF Units - Ratios/Supplemental Data						
Total Net Asset Value (\$) ⁶	40,082,212	41,043,080	40,766,891	37,642,125	2,838,431	1,055,018
Number of units outstanding ⁶	1,669,000	1,650,000	1,600,000	1,625,000	125,000	50,000
Management expense ratio ⁷	0.68%	0.67%	0.65%	0.68%	0.68%	0.69%
Trading expense ratio ⁸	0.06%	0.06%	0.06%	0.11%	0.25%	1.31%
Portfolio turnover rate ⁹	22.91%	73.30%	44.05%	59.63%	78.19%	341.86%
Net Asset Value per unit (\$)	24.02	24.87	25.48	23.16	22.71	21.10
Closing market price (\$)	24.02	24.86	25.51	23.16	22.63	21.07
Hedged ETF Units - Ratios/Supplemental Data						
Total Net Asset Value (\$) ⁶	202,400,342	189,187,745	154,484,891	75,062,124	8,984,401	2,349,306
Number of units outstanding ⁶	9,502,996	8,647,996	6,550,000	3,550,000	425,000	125,000
Management expense ratio ⁷	0.68%	0.68%	0.67%	0.68%	0.68%	0.69%
Trading expense ratio ⁸	0.06%	0.06%	0.06%	0.11%	0.25%	1.31%
Portfolio turnover rate ⁹	22.91%	73.30%	44.05%	59.63%	78.19%	341.86%
Net Asset Value per unit (\$)	21.30	21.88	23.59	21.14	21.14	18.79
Closing market price (\$)	21.32	21.91	23.71	21.16	21.08	18.80

Evolve Global Healthcare Enhanced Yield Fund

June 30, 2023

The Fund's Ratios/Supplemental Data (cont'd)

For the periods ended:	June 30, 2023	December 31, 2022	December 31, 2021	December 31, 2020	December 31, 2019	December 31, 2018
US Dollar Unhedged ETF Units - Ratios/Supplemental Data						
Total Net Asset Value (\$) ⁶	24,217,048	25,970,927	11,919,429	7,483,511	1,345,610	N/A
Number of units outstanding ⁶	876,038	901,038	400,000	275,000	50,000	N/A
Management expense ratio ⁷	0.69%	0.67%	0.65%	0.70%	0.00%	N/A
Trading expense ratio ⁸	0.06%	0.06%	0.06%	0.11%	0.25%	N/A
Portfolio turnover rate ⁹	22.91%	73.30%	44.05%	59.63%	78.19%	N/A
Net Asset Value per unit (\$)	27.64	28.82	29.80	27.21	26.91	N/A
Closing market price (\$)	27.70	28.81	29.85	27.21	26.91	N/A
Hedged Class A - Ratios/Supplemental Data						
Total Net Asset Value (\$) ⁶	1,165,252	1,025,711	1,507,193	1,053,714	N/A	N/A
Number of units outstanding ⁶	62,135	52,641	70,169	53,793	N/A	N/A
Management expense ratio ⁷	1.81%	1.80%	1.81%	1.78%	N/A	N/A
Trading expense ratio ⁸	0.06%	0.06%	0.06%	0.11%	N/A	N/A
Portfolio turnover rate ⁹	22.91%	73.30%	44.05%	59.63%	N/A	N/A
Net Asset Value per unit (\$)	18.75	19.48	21.48	19.59	N/A	N/A
Hedged Class F - Ratios/Supplemental Data						
Total Net Asset Value (\$) ⁶	3,808,336	1,010,940	619,093	197,392	N/A	N/A
Number of units outstanding ⁶	193,089	49,747	28,074	9,942	N/A	N/A
Management expense ratio ⁷	0.68%	0.68%	0.68%	0.67%	N/A	N/A
Trading expense ratio ⁸	0.06%	0.06%	0.06%	0.11%	N/A	N/A
Portfolio turnover rate ⁹	22.91%	73.30%	44.05%	59.63%	N/A	N/A
Net Asset Value per unit (\$)	19.72	20.32	22.05	19.85	N/A	N/A

6 This information is provided as at June 30, 2023 and December 31, 2022, 2021, 2020, 2019, and 2018.

7 Management expense ratio ("MER") is based on total expenses plus harmonized sales tax (excluding distributions, commissions and other portfolio transaction costs) for the stated period and is expressed as an annualized percentage of daily average net asset value during the period.

8 The trading expense ratio represents total commissions and other portfolio transaction costs expressed as an annualized percentage of average daily net assets during the period.

9 The Fund's portfolio turnover rate indicates how actively the Fund's portfolio manager trades its portfolio investments. A portfolio turnover rate of 100% is equivalent to the Fund buying and selling all of the securities in its portfolio once in the course of the period. The higher the Fund's portfolio turnover rate in a period, the greater the trading costs payable by the Fund in the period, and the greater the chance of an investor receiving taxable capital gains in the period. There is not necessarily a relationship between a high turnover rate and the performance of a fund.

Past Performance

The performance information does not take into account sales, redemption, distribution, income taxes payable by any unitholder or other optional charges that, if applicable, would have reduced returns or performance. The performance information shown assumes that all distributions made by the investment fund in the periods shown were reinvested in additional securities of the investment fund. How the Fund has performed in the past does not necessarily indicate how it will perform in the future.


Year-by-Year Returns

The bar chart below shows the Hedged, Unhedged, US Dollar Unhedged ETF Units', and the Hedged Class A and F Mutual Fund Units' performance for each of the financial years shown and for the six-month period ended June 30, 2023. The chart shows, in percentage terms, how much an investment made in the Fund on the first day of each financial period would have grown or decreased by the last day of that financial period.

Evolve Global Healthcare Enhanced Yield Fund


June 30, 2023

LIFE Hedged ETF Units¹




1 The Hedged ETF Units of the Fund effectively began operations on October 23, 2017.

LIFE/B Unhedged ETF Units²




2 The Unhedged ETF Units of the Fund effectively began operations on October 23, 2017.

LIFE/U US Dollar Unhedged ETF Units³



3 The US Dollar Unhedged ETF Units of the Fund effectively began operations on November 26, 2019. Returns presented based on NAV equivalent in USD.

Hedged Class A Mutual Fund Units⁴




4 The Hedged Class A Mutual Fund Units of the Fund effectively began operations on July 7, 2020.

Evolve Global Healthcare Enhanced Yield Fund

June 30, 2023

Hedged Class F Mutual Fund Units⁵



⁵ The Hedged Class F Mutual Fund Units of the Fund effectively began operations on July 7, 2020.

Summary of Investment Portfolio

All Positions

Security	Percentage of Net Asset Value (%)
Intuitive Surgical Inc.	6.5
Eli Lilly & Company	6.4
Medtronic PLC	5.5
Stryker Corporation	5.4
Abbott Laboratories	5.3
Novo Nordisk A/S, ADR	5.2
Merck & Company Inc.	5.1
Johnson & Johnson	5.1
Roche Holding AG, ADR	5.0
AstraZeneca PLC, ADR	4.9
Danaher Corporation	4.8
Sanofi, ADR	4.8
Novartis AG, ADR	4.8
Gilead Sciences Inc.	4.7
Bristol-Myers Squibb Company	4.6
CSL Limited, ADR	4.6
Pfizer Inc.	4.5
Amgen Inc.	4.5
Thermo Fisher Scientific Inc.	4.5
AbbVie Inc.	4.2
Total	100.4

Evolve Global Healthcare Enhanced Yield Fund

June 30, 2023

Industry Allocation

Portfolio by Category	Percentage of Net Asset Value (%)
Equities	
Health Care	100.4
Derivative Assets	0.1
Derivative Liabilities	(0.3)
Cash and Cash Equivalents	0.4
Other Assets, less Liabilities	(0.6)
Total	100.0

The summary of Investment Portfolio may change due to the ongoing portfolio transactions of the Fund. Updates are available quarterly by visiting our website at www.evolveetfs.com.



Evolve Global Healthcare Enhanced Yield Fund